New Phase 3 trial: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin — Adneuris Therapeutics, Inc.
Why now
Thesis: Early-stage pain trial with distant readout
Catalyst to watch: Enrollment completion and interim data
Main risk: Trial could fail or be discontinued
Why it matters
A new Phase 3 pain trial for cebranopadol signals pipeline progress for an unlisted sponsor.
Details
Sponsor: Adneuris Therapeutics, Inc.; Status: Recruiting; Conditions: Pain; Interventions: Cebranopadol 400 ug; Enrollment: 160 (estimated); First posted: 2026-09-28; NCT: NCT07845071
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC